ACS CAN Comments on FDA Draft Guidance on Postmarketing Studies

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on Postmarketing Approaches to Obtain Data on Under-Represented Populations in Clinical Trials Draft Guidance for Industry.